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Synthetic biology and therapeutic
strategies for the degenerating brain
Synthetic biology approaches can transform classical cell and gene therapies,
to provide new cures for neurodegenerative diseases
Carmen Agustın-Pavon and Mark Isalan
Synthetic biology is an emerging engineering discipline that
attempts to design and rewire biological components, so as
to achieve new functions in a robust and predictable manner.
The new tools and strategies provided by synthetic biology
have the potential to improve therapeutics for neurodegen-
erative diseases. In particular, synthetic biology will help
design smallmolecules, proteins, gene networks, and vectors
to target disease-related genes. Ultimately, new intelligent
delivery systems will provide targeted and sustained
therapeutic benefits. New treatments will arise from com-
bining protect and repair strategies: the use of drug treat-
ments, the promotion of neurotrophic factor synthesis, and
gene targeting. Going beyondRNAi and artificial transcription
factors, site-specific genome modification is likely to play an
increasing role, especially with newly available gene editing
tools such as CRISPR/Cas9 systems. Taken together, these
advances will help develop safe and long-term therapies for
many brain diseases in human patients.
Keywords:.artificial cell systems; genome editing;
neurodegeneration; synthetic proteins
Introduction
‘Our pleasures, joys, laughter, and jests arise from no other
source than the brain; and so do our pains, grief, anxieties,
and tears.’ Two millennia after Hippocrates first acknowl-
edged this simple truth, understanding how the brain works
is still one of our major challenges. Indeed, two ambitious
initiatives are currently devising tools for imaging and
controlling brain activity, ultimately to create a working
computational model of the entire brain [1]. Although
considerable scientific efforts are being made towards making
the 21st century the age of the brain, we still seem to have
caught just a glimpse of the function of the most complex
organ in the human body.
Understanding the healthy brain is one goal, working out
how to treat it when it becomes diseased is quite another.
Although human lifespan has increased as standards of living
have risen, the incidence of brain diseases has increased as a
consequence [2, 3]. Brain pathologies include neuropsychiatric
conditions, such as depression, as well as neurodegenerative
diseases – the former being a risk factor for the latter [4].
Taking both types of disorders together, up to one third of the
European population suffers from brain diseases every year [5].
Treating brain degeneration is now more necessary than
ever, but it is especially difficult for a number of reasons.
Putting aside our limited understanding of neural circuit
functions, the intricate mixture of cell types populating the
brain, the difficulty of targeted delivery, and the problem of
designing drugs capable of crossing the blood brain barrier
effectively (Fig. 1), we still face the daunting problem of
rewiring and restoring the neural circuits when some of their
components are lost as a result of degeneration. To circumvent
this problem, it is critical to make the earliest possible
interventions, ideally before neurodegeneration takes place.
In other words, the focus should be in targeting pathophysi-
ology rather than pathogenesis [6].
Discovering early biomarkers of disease is also essential,
so as to improve diagnostic tools and to identify early
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symptoms. For example, in most common neurodegenerative
conditions, early psychiatric symptoms such as depression
and anxiety may precede the onset of neuronal loss by one
or two decades. Some of these early symptoms are already
being tested in the clinic for diagnostic potential [7, 8].
Metabolic and molecular biomarkers could also enable
accurate predictions before the clinical onset of the disease,
but they need extensive validation, and they raise ethical
issues because of the unavoidable uncertainties associated
with prediction [9].
Even if efficient early diagnosis were possible, we
currently lack effective treatments for the degenerating brain.
Most available drugs merely alleviate symptoms, without
stopping disease progression or treating the underlying
causes. It is therefore essential to devise novel, efficient
therapeutic approaches to overcome these challenges; and,
fortunately, some new potentially game-changing ideas are in
the pipeline. These include the tools of synthetic biology, such
as protein and gene network engineering [10, 11], gene
targeting [12, 13] and genome editing [14–16].
In this review, we will look at the application of these tools
to advance gene and cell therapy for neurodegenerative
diseases. The discipline of synthetic biology is emerging with
the promise of building standard, programmable and reusable
parts for engineering biological systems [17]. It is beyond our
scope here to review the entire field, which is diverse. Very
briefly, synthetic biology includes topics such as: engineering
synthetic transcription, signalling and patterning networks
[18, 19]; engineering metabolic networks to produce useful
biomolecules (e.g. the malarial drug artemisinin [20]);
engineering multicellular systems (e.g. cellular logic gates
and computers [21]); building synthetic biomachines (e.g.
swimming ‘jellyfish’ made from heart cells [22]).
Synthetic biology can contribute to gene and cell therapy
for neurodegenerative diseases in several ways (Fig. 2). First,
it can be used to modify classical gene therapy vectors
for avoiding the immune system and yet for expressing
therapeutic transgenes at the appropriate time, location, and
quantity, to achieve long term therapeutic benefit. Second,
synthetic biologists can design new molecules to target
and modify expression in a tightly controlled manner.
Pathogenic genes can be targeted, while taking into account
their interactions in a given gene network. Genome engineer-
ing can be performed ex vivo in cells from different sources –
including patient-specific cells and induced-pluripotent
stem cells – or in vivo. Third, synthetic biomolecules can
be designed to interact and clear aberrant proteins. Finally,
it is possible to rewire genetic circuits in cells to build robust
artificial systems that perform tasks of interest. These can
then be delivered to the patient in the form of controllable
microencapsulated cells. By combining some of these new
approaches with classical gene therapy, we may obtain some
urgently needed solutions for the problems of neurodegener-
ative diseases.
How will gene therapy conquer
neurodegenerative diseases?
The idea of gene therapy is beautifully simple: by repairing,
replacing or modulating the activity of a diseased gene, you
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Figure 1. Overcoming the blood brain barrier for therapy. The
sketch shows the cellular components of the blood brain barrier
(BBB), which isolates and protects the neural tissue. The barrier
prevents most drugs and therapeutic molecules from reaching their
target sites in the central nervous system, when administered
peripherally. Several strategies can be used to overcome the BBB,
although these vary in their invasiveness. Recent developments
include the use of nanoparticles and ‘Trojan peptides’ that naturally
pass through lipid membranes to deliver their cargo. For a recent
review of advances in delivery systems to the central nervous
system, see [99].
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should be able to target the underlying causes of the
pathology directly. Gene therapy approaches typically deliver
genes or gene modulating factors (e.g. RNAi [23]) with viral
vectors. Standard vectors for use in the brain are adeno-
associated viruses (AAVs) [24] and lentiviruses [25]; these are
modified to infect cell subtypes efficiently while addressing
safety concerns by being non-replicating. Single gene diseases
are easier to target and, in the context of neurological
diseases, these include the metabolic disease of metachro-
matic leukodystrophy [26] and Huntington’s disease (HD) [27].
However, even single gene diseases are not always straight-
forward to tackle, because we often have a limited
understanding of the multiple interactions of single genes
embedded within larger disease-causing networks.
Neurodegenerative diseases such as Parkinson’s (PD),
Alzheimer’s disease (AD), or amyotrophic lateral sclerosis
(ALS), are generally complex (Box 1), hence making it difficult
to choose a single gene to target, – although several trials are
in development (Table 1). The preferred approach so far has
therefore been that of neuroprotection, via the administration
of neurotrophic factors (factors that promote the growth,
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Figure 2. Overview of synthetic biology approaches for tackling
neurodegenerative diseases. The sketch shows a marble bust of
Hippocrates, who recorded some of the earliest insights about the
functions of the brain. Note that many of the approaches can be
used in combination.
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survival and maintenance of neurons) or by promoting their
synthesis [6]. Cell transplantation of bioengineered cells
secreting neurotrophic factors is another promising strate-
gy [28, 29], but requires overcoming problems such as the
limited distribution of factors in brain tissue, and the limited
controllability of the release (Table 1). Synthetic biology has
the potential to improve these approaches both by modifying
the gene delivery vectors and by providing new payloads to
control gene expression.
Modifying gene therapy vectors reduces
host clearance of therapeutic transgenes
Before discussing the possible genetic payloads that will be
used in the next generation of gene therapy studies, it is
important to consider the problem of long-term therapeutic
expression of transgenes in the brain and vector design.
Dramatic problems, such as the sudden death of a young
patient in a gene therapy trial, as a direct consequence of viral
vector infusion [30], have driven researchers to improve the
safety of the viral vectors, by reducing the immunogenicity of
vector capsid proteins [31]. Another well-documented adverse
effect has been insertional mutagenesis – the development of
cancerous cells after insertion of the vector in the host
genome [32]. As a result, researchers have worked to reduce
genomic insertion capabilities [33]. Nevertheless, the devel-
opment of increasingly safe vectors does not necessarily imply
successful gene therapy, for it is also necessary to consider the
toxicity and immunogenicity of administered genes. A striking
example of this issue has been shown recently in a series of
papers using rodents and non-human primates, simply using
the common reporter gene GFP [34–36].
GFP is ubiquitous in modern biological research, and on
the whole no toxicity is reported. However, it has been
demonstrated that brain injections of an AAV vector
Box 1
Common and ‘rare’
neurodegenerative diseases
Parkinson’s and Alzheimer’s disease are two of the most
common neurodegenerative diseases of the brain. Both
can be idiopathic or familial, and a number of different
genes have been related to each condition. For AD,
these include amyloid-b, presenilins, tau, and apolipo-
protein E. For PD, genes include a-synuclein, parkin, or
Leucine-rich repeat kinase 2. The multifactorial nature of
these diseases makes them intrinsically more difficult to
understand and to treat.
By contrast, HD has a single cause, but occurs more
rarely with a frequency of approximately 1:10,000 people.
HD belongs to a family of nine neurodegenerative
disorders known as polyglutamine diseases, caused by
the expansion of glutamine stretches codedwithin several
unrelated genes. HD shares some features with PD and
AD, including onset in late adulthood (for shorter polyglut-
amine expansions), selective neuronal vulnerability to
disease-related proteins and abnormal protein processing
and aggregation. Thus, HD is gaining importance as a
model disease for developing therapeutic strategies that
might translate across to the more common neurodegen-
erative diseases of diverse aetiology [27].
Similarly, whereas most of the cases of the motor
neuron disease ALS are sporadic, the rare disease spinal
muscular atrophy (SMA) is monogenic, making it an ideal
candidate for gene therapy studies [100]. SMA has a
similar prevalence to HD, and can be caused by several
mutations in the autosomic Survival Motor Neuron gene
(SMN1). These include intragenic deletions, nonsense
and point mutations, which reduce the production of
SMN protein.
Table 1. Recent clinical trials illustrating strategies in gene and cell therapy for neurodegenerative diseases, showing trial
outcomes and potential improvements from synthetic biology tools
Disease Therapeutic approach Outcome Reference
Improvement with synthetic
biology tools
AD Antibody against amyloid b Safety [110] Improved specificity, tailored
antibody engineering
Encapsulated cells delivering NGF Safety, low delivery levels
after retrieval
[29] Tightly controlled delivery levels
PD Transplantation of levodopa-producing
cells
No improvement [111] Improvement in delivery and
distribution
Gene therapy: administration of
neurotrophic factor
Safety [24] Improvement in delivery control
and distribution
Gene therapy: administration of
rate-limiting enzyme for dopamine
Safety and short term efficacy [112] Improvement in delivery and
distribution
Transplant of fetal cells Long term improvement in
two patients
[113] Synthetic non-fetal stem cells
SMA Antisense oligonucleotides for
RNA editing
Safety and dose-dependent
muscle function improvement
[45] Fully synthetic antisense
oligonucleotides
As noted in the main text, the outcome of the treatments might critically depend on early administration, i.e. growth factors might be able to
slow disease progression, but they will not rescue neuronal death. AD, Alzheimer’s disease; PD, Parkinson’s disease.
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expressing GFP leads to a strong immune response against the
foreign protein, and neuroinflammation 3–4 weeks post-
injection, causing significant neuronal loss [35, 36]. In
addition, in rats, the infusion of a human gene leads to even
stronger inflammatory responses, lasting at least 8 weeks after
injection, with high neuronal loss [34]. Thus, there is the risk
that simply administering transgenes coding for foreign or
synthetic proteins could trigger immune reactions in the
brain.
To reduce this risk, it is possible to use bioinformatics tools
for designing non-immunogenic constructs with fewer
predicted epitopes [37]. The resulting genes can be synthes-
ised at a DNA level, including suitable host-optimised codons
as well as coding host-like protein sequences. It should be
noted that some foreign therapeutic transgenes will be easier
to host-optimise than others. For example, out of the various
DNA targeting systems (discussed in detail in Genome editing
with artificial nucleases, below), only zinc fingers (ZFs) are
native to mammalian systems. ZFs are thus easier to modify to
remove immunogenic epitopes than, say, the prokaryotic
TALE and CRISPR/Cas systems [38–40] (Table 2).
To ensure the safety and success of synthetic foreign
transgenes in the brain we need to carry out long-term studies
and model the possible off-target effects of the introduced
transgenes. Even when the outcome is simply the repression
of a mutated gene causing the disease, we need realistic
models of how the perturbation in the diseased network
affects the organism. Reversion of the system to its original
‘state’ is not a guaranteed outcome of expressing a therapeutic
gene. In the case of neurotrophic factors, an additional level
of modelling complexity is added by the fact that they are
secreted, and will affect multiple cells, including non-
transduced ones. Overall, synthetic genetic constructs need
to be engineered sympathetically to the host organism, ideally
with some systems-level understanding of the major gene
expression and metabolic pathways prevalent in the target
tissue.
New synthetic payloads enable gene
targeting, regulation, and editing
Moving beyond the general considerations of delivery vector
design, synthetic biology tools can provide a series of new
therapeutic payloads for treating neurodegenerative diseases.
The general aim is to control the expression of target genes so
as to prevent the loss of discreet populations of neurons, while
Table 2. A comparison of genome editing tools
Structure and mechanism of DNA recognition Origin Used since Pros Cons
Zinc finger nucleases. Single aa within each
ZF helix bind single DNA bases,
each finger recognizes 3–4bp
Eukaryotic
transcription
factor motifs
2001
[16, 114, 115]
Low toxicity and
immunogenicity in
mammalian cells
Economical size:
bind 1bp/10 aa
Can concatenate
to make long
chains.
Difficult to
engineer
Less good at
binding AT-rich
DNA
Need to design
overlap between
fingers
TALENs (Transcription activator-like effector
nucleases). Two-aa residues within each
34 aa unit specifically recognise 1bp
Prokaryotic host
defense
mechanism
Xantomonas
plant
pathogen
2010
[60, 116]
Easy to engineer
Full modularity to
make long chains
Large and
repetitive
constructs:
bind 1bp/33 aa
Less good at
binding G-rich
DNA
Immunogenicity
CRISPR/Cas9 (clustered regulatory interspaced
short palindromic repeats). RNA serves as a guide
for the Cas9 nuclease,
recognising 20bp
Prokaryotic
‘immune’ system
against
bacteriophages
e.g. Streptococcus
pyogenes
2013
[105, 117]
Quick and easy to
bind new targets
No protein
engineering
High efficiency
Lower specificity:
14/20bp per
complex
Can use paired
complexes for
higher specificity,
but not full
concatenation
Immunogenicity
aa, amino acid; FokI, nuclease domain from FokI restriction enzyme.
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enhancing the expression of neurotrophic factors to promote
neuroprotection and self-recovery. Further to the RNAi-related
developments of the last decade, synthetic biology has the
potential to engineer transcription factors to control disease-
related gene expression.
‘Killing the messenger’: RNA silencing and
editing technologies are reaching maturity
One of the most tried and tested gene therapy strategies so far
has been the silencing of mutated transcripts by means of
antisense and RNA interference (RNAi) molecules. The use of
chemically-modified nucleic acids to build stable small
hairpin oligonucleotides (shRNAs) or microRNAs (miRNAs)
has helped in this direction.
A pre-clinical study that successfully used this approach
provided a safe, long-term treatment in several mouse models
of HD. Targeting the mutant huntingtin mRNA gene with
antisense 20-O-methoxyethyl-phosphorothioate-modified chi-
meric oligonucleotides led to its degradation with RNAse
H [41]. This approach provided significant reductions of the
mutant proteins for twomonths after treatment, in early-onset
HDmouse models, and reversal of the motor abnormalities for
six months after treatment, in a late-onset mouse model.
Importantly, this treatment reduced the mRNA levels of
huntingtin in a non-human primate for eight weeks after the
termination of the treatment [41], highlighting its potential in
translational medicine.
Similar modified oligonucleotides are already being
translated to the clinic for spinal muscular atrophy (SMA)
(Box 1). The Survival Motor Neuron gene (SMN1) is mutated in
the disease, but the therapeutic strategy takes advantage of
the presence of an almost identical gene variant (SMN2). SMN2
contains an RNA splicing site that excludes exon 7 and
produces a non-functional protein [42]. However, antisense
oligonucleotides can silence this splice site to promote the
inclusion of exon 7, thus rescuing SMA. After successful pre-
clinical studies in mouse models [43, 44], several clinical trials
are being developed [45] (Table 1).
As well as targeting mRNAs that code for disease-related
proteins, recent studies are tackling non-coding RNAs that are
also involved in pathogenesis [46]. For example, a GGGGCC
expansion is found in the promoter and first intron of the
C9ORF72 gene, that makes a toxic non-coding transcript. This
mutation is found in both ALS and frontotemporal dementia
patients. Targeting the transcript with antisense oligonucleo-
tides thus provides a promising common strategy for two
different neurodegenerative diseases [47].
Although generally safe, some of these interference
strategies are not devoid of peril for the organism. For
example, shRNA has sometimes been found to be toxic in the
brain [48–51], most likely because of saturation of the
endogenous miRNA machinery, or because of off-target
effects. A step forward in this strategy is the use of novel,
fully synthetic, genetic polymers [52]. These polymers, based
on nucleic acid architectures not found in nature, can have the
advantage of not being recognised by cellular enzymes and
processing machinery, hence reducing the possibility of
rejection, while retaining therapeutic potential.
Synthetic transcription factors can
flexibly regulate disease target genes
Whereas RNAi is generally limited to inhibiting target
expression, artificial DNA binding proteins can be targeted
to virtually any sequence, and can be fused to either
transcription repression or activation domains [53, 54].
For example, we designed and built a long poly-ZF protein
able to bind to expanded stretches of CAG repeats, a mutation
found in polyglutamine disorders, such as HD (Box 1). We
fused our custom-made ZF to a KRAB repressor domain, and
this synthetic transcription factor was efficient in repressing
mutant huntingtin in human patient cell lines [12]. The ZF was
vectorised using AAV, and was delivered to mouse brains in
the R6/2 HD model. This resulted in an acute reduction of the
levels of mutant RNA and protein, and a concurrent delay in
the onset of HD symptoms [12].
A similar approach was used in the neurons of the
retina, as a treatment for retinitis pigmentosa. This disease
causes blindness because of a mutation in rhodopsin. In a
mouse model overexpressing mutated human rhodopsin,
retinal injections of a viral vector carrying an engineered
ZF, coupled to a transcriptional repressor, reduced tran-
scription levels of mutated rhodopsin and prevented retinal
degeneration [55].
Synthetic transcription factors have also been used to
upregulate the transcription of endogenous neurotrophic
factors. Generally, the virally-derived VP16 or VP64 transcrip-
tion activation domains can be fused to any DNA binding
domain to make activators [56, 57]. In a rat model of PD, a
synthetic ZF coupled to the activator domain targeting the
endogenous glial-derived neurotrophic factor (GDNF) pro-
moter, was indeed neuroprotective [58]. When following this
strategy, it is important that the expression levels of the
enhanced gene do not exceed the normal physiological range,
since this risks toxicity [59]. The therapeutic potential of
artificial gene regulation is great, and, it is complemented by
another level of synthetic biology: manipulating the genome
at will.
Genome editing with artificial nucleases:
A geneticist’s dream
Perhaps the most transformative technology to emerge in the
last decade has been the possibility to harness the power of
synthetic nucleases to allow genome-editing [16, 60, 61]
(Table 2). Nucleases make targeted double-stranded DNA
breaks, which naturally induce knockouts (by the process of
error-prone non-homologous end-joining) or knock-ins (by
homologous recombination). Zinc finger nucleases (ZFNs),
Transcription Activator like Effectors (TALENs) and, most
recently, RNA-guided Clustered Regularly Interspaced Short
Palindromic Repeat systems (CRISPR/Cas9), allow easy and
efficient genetic engineering of mammalian cells. In particu-
lar, the latest generation of lentiviral Cas9 systems can
reach genome modification efficiencies of >90% of targeted
cells [14] – this would have seemed like science fiction just a
few years ago.
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Synthetic nucleases can be used to knock out, mutate, or
repair a gene causing a given disease. One of the most
promising aspects of this approach relies on the editing of
human pluripotent stem cells for autologous transplants [62].
An example is the recent success using ZF nucleases to delete
the CCR5 HIV receptor in white blood cells, demonstrated to be
a potential functional cure for HIV in patients [63].
Haematopoietic cell transplants, using engineered cells
corrected for a mutation, have already shown promise for
neurodegenerative diseases arising from metabolic defects,
and therefore such diseases could also be treated with the
latest generation of synthetic nucleases. Amongst these,
lysosomal storage diseases are fatal conditions in which the
accumulation of cell by-products in lysosomes leads to
neurodegeneration. In metachromatic leukodystrophy, the
deficiency of a single enzyme, arylsulfatase A, leads to fatality
in infancy, within a few years of disease onset. Recently, a
clinical trial has successfully used the autologous transplan-
tation of engineered haematopoietic cells expressing the
functional enzyme. These cells can migrate to the brain and
clear the toxic accumulations of the enzyme substrate [26].
The use of new genome editing technologies will greatly
improve the efficiency and safety of genome editing with
such aims, by integrating transgenes at specific loci, using
homologous recombination.
The challenge of target specificity of synthetic nucleases is
being actively researched and refined [64]. Researchers are
devising methods to improve specificity and avoid potential
off-target effects, such as using DNA nickases rather than
full cleavases [65]. Nickases induce breaks in just one DNA
strand, and they enhance homology-directed repair without
activating non-homologous end joining repair. Although
the CRISPR/Cas9 system is rapidly emerging as the easiest
system to apply – simply requiring cloning of a guide RNA
sequence to reprogram nuclease specificity – it originally had
a weakness in terms of target specificity. Generally,>18 bp are
required to specify a unique locus in the human genome.
Although the CRISPR/Cas9 recognition complex covers 20 bp,
6 bp of the DNA recognition site tolerates mismatches,
opening up the possibility of off-target effects. By combining
two nickases, Ran et al. effectively doubled the specific
binding target length, making unwanted off-target effects far
less likely [66]. The use of bioinformatic tools to predict off-
target effects can also increase target specificity [67].
CRISPR systems are very practical, but some applications
will require sustained expression, and in vivo studies have not
yet investigated the long-term consequences of expressing
these bacterial factors in the brain. The prokaryotic TALE
effectors have also only been used for short studies: for
example, when a light-controlled TALE was injected in mouse
brain [68], animals were sacrificed only eight days post
injection. By contrast, we have used eukaryotic ZFs to
modulate the gene causing HD for up to four weeks in mouse
brains [12], and can potentially make the entire protein
sequence mouse-like, to avoid the immune system.
While in vivo techniques may be essential for complex
diseases such as PD, in which discreet populations of neurons
are lost, single-gene metabolic neurodegenerative diseases
naturally suit the more tractable ex vivo approaches. As well
as not having to consider immune rejection, one can deliver
genome editing tools in the form of RNA ex vivo, hence
eliminating the risks of long-term expression or unwanted
random integration. Moreover, if stem cells can be modified,
they can provide a long-term therapeutic benefit [62, 63].
Pluripotent stem cell transplant technology for the brain is
still in its infancy, and it is still not clear how genome-edited
neurons would be rewired correctly. While this major hurdle
will require further research, genome editing already has
other useful applications such as creating disease models
(Box 2).
Engineering approaches improve the
clearance of aberrant proteins
One of the commonhallmarks of neurodegenerative diseases is
the aggregation of mutated proteins that possess seeding
activity and can be transmitted in a prion-like fashion [69].
A strategy to prevent aggregation is the administration of
antibodies targeting these proteins. The advantage of this
approach is that the antibodies can be delivered directly to the
brain with minipumps, without the use of viral vectors, and
without the need of modifying the genome, hence preventing
undesired off-target effects. For example, a recent study in
a mouse model of AD showed that selected antibodies
administered chronically for three weeks to the brain ventricle
decreased aggregation and improved cognitive deficits [70].
These antibodies can also be administered as vaccines against
prion-like diseases, and several clinical trials are on-going [71].
Monoclonal antibodies are expensive to generate, however,
and their production requires the use of living animals.
Synthetic antibodies made by protein engineering offer a good
alternative to naturally generated antibodies, with the
possibility of improved specificity [72].
Antibodies are not the only peptides that can help clear
mutant protein aggregates. Interactions with some natural
proteins prevents aggregation and may be used as a
therapeutic approach [73]. Bauer et al. [74] tackled mutant
Huntingtin protein in HD by designing a polyglutamine-
binding peptide, fused to heat shock cognate protein 70
binding motif, such that it would promote degradation of
aggregates by chaperone-mediated autophagy. Impressively,
AAV delivery of this synthetic protein had a strong therapeutic
effect in the R6/2 HD mouse model. Thus, synthetic biology
principles can be used for the design and production of
engineered proteins that will act with high affinity to target
mutated proteins and prevent aggregation.
Synthetic gene circuits: Creating
intelligent genetic therapies
Synthetic biology can go beyond designed therapeutic
proteins, expressed by simple promoters, and can achieve
the precise control of gene expression by means of new
promoter designs, gene switches, and circuit engineering.
Current gene therapy vector constructs utilise a relatively
limited range of promoters to drive transgene expression. The
....Prospects & Overviews C. Agustı´n-Pavon and M. Isalan
985Bioessays 36: 979–990, 2014 The Authors. Bioessays published by WILEY Periodicals, Inc.
P
ro
b
le
m
s
&
P
a
ra
d
ig
m
s
combined CMV enhancer chicken b-actin (CAG) promoter and
woodchuck hepatitis virus post-transcriptional regulatory
element (WPRE) [75] are widely used for strong constitutive
expression, whereas cell-type specific promoters are often
used to limit transgene expression to subsets of cells [76, 77].
Since quantitative promoter characterisation is a key aspect
of synthetic biology [78, 79], new promoters should become
available as a result.
Gene switches, based on small molecules or drugs
administered to the patient, also have great potential for
building conditional expression constructs in the brain. For
example, the synthetic steroid hormone mifepristone –
commonly used to treat Cushing’s syndrome [80] – has been
used as a gene switch in the brain. Mifepristone activated the
production of GDNF, resulting in a neuroprotective treatment
in a rat model of PD [81]. Furthermore, in some cases, the
switch molecule can also directly treat disease symptoms,
resulting in double treatments [82].
An alternative and increasingly popular genetic switch is
light-driven: optogenetics has revolutionized the field of
neuroscience because of its precision and rapid kinetics [83].
Light-controlled systems have successfully modulated neuron
specific genes both in primary culture [84] and in the brains of
mice: a TALE binding domain fused to plant cryptochrome 2
(sensitive to blue light) thus interacted conditionally with its
partner protein CIB1, itself fused to an activator domain [68].
Moreover, the use of fibre optics devices for gene control in the
brain is feasible. Implanted electrodes for stimulation are
already in use for PD patients [85], and experimental models
in which neuronal activity is controlled in vivo by optogenetic
techniques is achieving great refinement [86].
Moving from switches to full genetic circuits, perhaps
the most exciting developments will come from intelligent
constructs that integrate multiple inputs to get conditional
outputs. Mammalian gene circuit engineering is still in its
infancy, and most examples still focus on systems to make
desired patterns of gene expression [19, 87]. However, several
research projects are developing genetic logic gates, analo-
gous to the gates used in electronics [10, 11]. For example, AND
gates require two simultaneous activation inputs, such as the
Box 2
Genome editing for neurodegenerative disease models
Synthetic nucleases have already been used to create brain
disease models. For example, using ZF nucleases, PD, and
AD model cell lines expressing mutations were created and,
conversely, mutations in patient-derived induced pluripotent
cells were corrected [101, 102]. Such techniques not only
underpin the hope that we will be able to model diseases in a
dish [103], building systems at will in order to increase our
understanding, but they also pave theway for future therapies
based on genome-edited patient stem cell transplants.
Although useful, cell culture approaches unfortunately
cannot recapitulate the complex environment of an organism
completely; factors such as immunity and cell-cell commu-
nication are of extreme importance. Moreover, the common
inbred rodent models used are far removed from many
aspects of human physiology in terms of both size and
genetic diversity. Reflecting the move towards more
personalised medicine, synthetic biology tools are helping
to develop genetically modified animal models beyond the
mouse, more rapidly and more efficiently [104–106]. For
example, using three plasmids coding TALENs, the MECP2
gene was knocked down in monkey embryos with no
detectable off-target mutations [107]. MECP2 deficiency is
the cause of Rett syndrome, a severe neurodevelopmental
disorder affecting only females (since the mutation is lethal
for male embryos). A non-human primate model of this
disease will help to shed light on the autism-related
phenotype, and will enable more efficient and realistic pre-
clinical trials. Potentially, thismethod could be used to create
other neurodegenerative disease models in any non-human
primate species, such as marmosets (see picture), an
increasingly popular model species for neuroscience
research due to its small size, ease of breeding and brain
features comparable to humans [108, 109].
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binding of heterodimer parts of transcription factors, to
achieve conditional expression of a desired output gene
(Fig. 1). Based on similar principles, cancer-detection circuits
are being developed [13, 88], and it is only a matter of time
before these are adapted to gene therapy applications.
Will artificial cell transplants achieve
long-term neuroprotection?
One of the most ambitious aims of synthetic biologists is to
create synthetic cells equipped with tightly regulated gene
networks to transplant into host organisms. These would
release therapeutic compounds in a controlled manner to
help organisms to self-repair. Such cells need to be carefully
isolated from the host to prevent immune rejection and
undesired proliferation. This is achieved by encapsulation
with a biocompatible, semipermeable material, such as
alginate-poly-(L-lysine)-alginate, which allows the exchange
of essential biomolecules and ions, while isolating the cells
from the immune system of the host [82, 89, 90].
In recent work following this strategy, a biosensor cell was
built that could sense a change in the neurotransmitter
dopamine, which is involved in processes such as movement
andmotivation [91]. The D1 dopamine receptor was coupled to
an intracellular signalling cascade to activate the production
of atrial natriuretic peptide (ANP), a natural anti-hypertensive
molecule. Implanting these genetically engineered encapsu-
lated cells in the peritoneum of hypertensive mice demon-
strated that the production of ANP was enhanced in a
controllable way by dopamine agonists or sexual arousal. This
reduced and controlled the blood pressure of the mice in both
situations [89].
Pharmacological and gene therapies can be combined for
diseases with multiple symptoms. To treat metabolic syn-
drome, a chimeric TAAR (trace amine-associated receptor,
coupled to G protein) was rewired to activate two genes
controlling food intake, namely glucagon-like peptide 1 and
leptin. The chimeric receptor responds to guanabenz, a drug
clinically prescribed to treat hypertension. Microencapsulated
cells bearing this system were implanted in the peritoneal
cavity of mice. This double treatment was successful in
attenuating several symptoms of metabolic syndrome in obese
mice [82].
Encapsulated cells have long been used to release
neurotrophic factors in the treatment of neurodegenerative
diseases [90], but the main outcomes of those clinical trials
have been the general safety of the implants, rather than
strong therapeutic results. Problems have included the limited
distribution of secreted neurotrophic factors, and fluctuating
production and responses, caused by circadian rhythms.
Mammalian synthetic biology researchers are building
artificial oscillators, inspired by circadian clocks [92], and
tunable secretion and cell-cell communication systems [19].
In the future, we may build more complex sender-receiver
systems, including feedback elements that enhance the
distribution of secreted therapeutic factors.
As noted in the introduction, successful treatments for
neurodegenerative diseases require molecular biomarkers for
accurate early prediction. It was recently discovered that the
depletion of ten lipids in peripheral blood predicts the
occurrence of amnestic mild cognitive impairment or AD
within 2–3 years, with over 90% accuracy [93]. Similarly, an
auto-antibody against a potassium channel, whose dysfunc-
tion is related to neurodegeneration [94], was found in
multiple sclerosis patients before symptom onset [95]. If such
biomarkers could be linked to biosensor circuits in encapsu-
lated cells [96], for the conditional production of neurotrophic
factors, one could envisage predictive and protective strate-
gies for neurodegenerative diseases. These would aim to delay
onset and to slow disease progression, and would be targeted
to susceptible populations.
Artificial cells can also be used to release specific factors
for the promotion of self-repair. Adult neurogenesis is active in
some specific niches in the human brain, and this process is
dysregulated in neurodegenerative disorders [97]. The recent
discovery of adult neurogenesis in the human striatum [98]
opens the exciting possibility of investigating the regulatory
factors required for cell migration and differentiation. A
deeper knowledge of the factors, and their roles in diseases
like HD and PD, would allow the design of regulators to
enhance these processes, perhaps in combination with
neuroprotection. Another issue is that projection neurons
(large neurons wiring main circuits) are lost in such diseases,
while adult-produced cells only differentiate into interneur-
ons (small neurons that modulate the main circuits) and glia.
The challenges are to design regulators that could further
influence the fate of the progenitors to differentiate into
projections neurons, and to promote rewiring.
Conclusions and outlook
Synthetic biology can provide many useful approaches for the
rational design of therapeutic factors and intelligent systems
to treat a variety of diseases, including targeting the most
complicated organ in our body, the brain. We can already find
examples of the design of factors for genome editing, the
regulation of gene expression, protein targeting, and for
biosensor cells able to release therapeutic molecules in a
tightly regulated manner, both in response to endogenous
signals or to drugs. With all these new tools, we will be able to
repair or to complement the pathogenic genes in specific
conditions, such as those with single-gene metabolic causes.
For many diseases, we will need to establish combined
protective and restorative actions. Harnessing natural pro-
cesses to promote self-repair and an improved basic
knowledge of the underlying development and circuitry of
the brain will be essential for developing new synthetic
therapies that act in concert with host physiology. Early
detection and intervention is crucial for beating the devasta-
tion caused by neurodegeneration. Perhaps the most exciting
long-term possibility is to link biomarkers to biosensors, to
express effectors conditionally, and to reverse pathogenesis as
early as possible. Although thework has begun, we still need a
lot more research to design a safe and long-term gene or cell
therapy based on synthetic biology principles. Using nature as
our inspiration, we will continue to improve our intelligent
synthetic designs.
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